Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2265278/incyte-s-incy-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2265278
Apr 30, 2024 - Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
0
SHY: There Are Cheaper Ways To Access Treasuries
https://seekingalpha.com/article/4677290-shy-there-are-cheaper-ways-to-access-treasuries?source=feed_tag_etf_portfolio_strategy
Mar 11, 2024 - SHY provides exposure to short-term U.S. Treasury bonds and offers stability and attractive yields. Learn why the Fund is a good option for those seeking stability, attractive yields.
0
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2225655/incyte-s-incy-q4-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2225655
Feb 13, 2024 - Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
0